sutures newsletter


P & T Approvals, FDA Warnings About DPP-4 Inhibitors, Canagliflozin

Pharmacy Focus

See highlights of the August meeting of the Pharmacy and Therapeutics Committee. Also, the U.S. Food and Drug Administration has issued a warning about DPP-4 inhibitors and joint pain and has strengthened its warning about fracture risk with canagliflozin.

Mark Your Calendar

Surgery Grand Rounds

Click the "read more" to see information about upcoming Surgery Grand Rounds.

Grand Rounds

Click here to view a schedule of all upcoming grand rounds.

Education Schedule

Click the PDF links below to see the Department of Surgery's education schedule.

Education Schedule - September 2015 (PDF)

Education Schedule - October 2015 (PDF)

Surgery Scheduling

Click the "read more" for hours and contact information for surgery scheduling.

Share Your News

Know an interesting colleague we should profile? A story we should tell? Submit your ideas, meetings and events for consideration.

Click here to submit your news to Sutures

Cardiothoracic Surgery Sees Encouraging Growth

By Alfredo Trento, MD
Professor of Surgery
Estelle, Abe and Marjorie Sanders Chair in Cardiac Surgery
Director, Cardiothoracic Surgery
Cedars-Sinai Heart Institute

The Division of Cardiothoracic Surgery has grown significantly over the past several years. We perform a complete range of surgical interventions and have recently achieved a new high of 1,479 adult cases for fiscal year 2014-15.

Cedars-Sinai is nationally and internationally recognized as a primary CT surgery robotic program center. Robotic-assisted mitral valve repair cases are growing on an annual basis, with mitral repair procedures performed since 2005 approaching 550 cases.

The Heart Transplant Program is the largest in the world with a world record number of heart transplants per year for the past three years (95 in 2012, 119 in 2013, 122 in 2014 and 94 this year as of Aug. 31).

The Mechanical Circulatory Support (MCS) Program has also grown substantially over the past year. Francisco Arabia, MD, introduced the Total Artificial Heart (TAH) as a new MCS device, making Cedars-Sinai the largest implanting center in the nation. Currently there are two TAH clinical trials:

  • SynCardia 50cc TAH used as a bridge to transplant in smaller patients who are waiting for a suitable donor heart
  • SynCardia 70cc TAH implanted for destination therapy in those not eligible for a heart transplant

The SynCardia Total Artificial Heart has been introduced as a mechanical circulatory support device.

The Extracorporeal Membrane Oxygenation Program (ECMO) Program, directed by Danny Ramzy, MD, has increased to a new high of 77 implants in fiscal year 2014-15. We consistently have two to three patients on ECMO per week.

The Aortic Program also has grown under the direction of Ali Khoynezhad, MD. The complexity and spectrum of aortic pathologies treated has increased substantially, making Cedars-Sinai's program the largest on the West Coast.

We maintain the distinction of having the largest implanting program for transcatheter aortic valve replacements in the nation. Wen Cheng, MD, is the cardiothoracic surgeon who implants the devices in collaboration with interventional cardiologist Raj Makkar, MD.

I continue to work closely with Saibal Kar, MD, to implant the MitraClip device under the COAPT study, for which I am the surgical co-investigator.

In collaboration with Kar and Makkar, we will begin a transcatheter mitral valve replacement program in the near future.

Overall, the growth of the Division of Cardiothoracic Surgery has given Cedars-Sinai national and international distinction. I move forward with confidence and optimism in the coming year.